•  
  •  
  •  
  •  

2026-07-21 05:11:28

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • RITES & MECON sign MoU to explore business avenues
  • California Software Company Q1 FY27 Results: Consolidated Net Profit Surges 2,071% YoY to ₹4.19 Crore; Revenue Up 329%
  • Swastika Investmart Q1 FY27 Results: Consolidated Net Profit Rises 14.5% YoY to ₹3.76 Crore; Operational Revenue Up 10%
  • Golden Legand Leasing and Finance Q1 FY27 Results: Net Profit Drops 88.8% YoY to ₹54.89 Lakh Amid Top-Line Contraction
  • Authum Investment & Infrastructure Q1 FY27 Net Profit Rises 17.5% YoY to ₹1,108 Crore; Total Income Up 21.3%

Keywords Selected:  Analytics

Stock Report

  • LatentView Analytics appoints Sonal Ramrakhiani as Chief Executive Officer to Accelerate Global AI-Led Growth
  • Fractal Launches Cogentiq E-Commerce: AI that Acts on Profit Signals in Minutes
  • Fractal Reports Profit Growth of 109% for Q4
  • Indegene Limited recommends final dividend of Rs. 2.25
  • Indegene Reports 32.8% YoY Growth in Q4FY26, Crosses ₹1,000 Crore Quarterly Revenue
  • LatentView Analytics Invests $3m in Healtheon AI
  • Fractal introduces LLM Studio to Bring Enterprise-Grade GenAI Customization with NVIDIA NeMo and NVIDIA NIM Microservices
  • Fractal unveils intelligent sales agents to accelerate B2B growth
  • Fractal Launches PiEvolve, an Evolutionary Agentic Engine for Autonomous Machine Learning and Scientific Discovery
  • Colab Platforms has successfully incorporated its wholly owned subsidiary, Colab Intelligence Pvt. Ltd.
  • Latent View Analytics Ltd reports Rs. 44.39 crores consolidated net profit in Q2 FY2026
  • Indegene Strengthens Consulting Practice to Accelerate Life Sciences Transformation
  • Aditya Infotech appointed Authorised Distributor for Seagate's Advanced Video and Analytics Storage Solutions in India
  • Indegene announces acquisition of BioPharm to Expand AI-Driven Marketing and AdTech for Global Pharma
  • Datavant and Indegene Partner to Power More Efficient Clinical Trial Recruitment
  • Indegene Expands India Footprint, Opens New Center in Pune
  • Indegene Wins Gold for Gamified Learning and Development Approach at Brandon Hall Group's HCM Excellence Awards 2025
  • Indegene Launches NEXT Medical Writing Automation to Streamline Complex Medical Writing Workflows with GenAI
  • Indegene Identified as a Leader in ISG's Provider Lens™ Evaluation for Life Sciences Digital Services in Commercial Operations - Digital Evolution (Service Providers) Quadrant 2025
  • The Indian School of Public Policy and Indegene announce strategic collaboration
  • Latent View Analytics Ltd consolidated Q4 FY2025 PAT up at Rs. 53.47 crores
  • Indegene Limited recommends final dividend of Rs. 2
  • Indegene expands presence in Europe, announces New Center in London
  • Financial Times Names Indegene Among High-Growth Companies in AsiaPacific 2025

Latest Post

  • RITES & MECON sign MoU to explore business avenues
  • California Software Company Q1 FY27 Results: Consolidated Net Profit Surges 2,071% YoY to ₹4.19 Crore; Revenue Up 329%
  • Swastika Investmart Q1 FY27 Results: Consolidated Net Profit Rises 14.5% YoY to ₹3.76 Crore; Operational Revenue Up 10%
  • Golden Legand Leasing and Finance Q1 FY27 Results: Net Profit Drops 88.8% YoY to ₹54.89 Lakh Amid Top-Line Contraction
  • Authum Investment & Infrastructure Q1 FY27 Net Profit Rises 17.5% YoY to ₹1,108 Crore; Total Income Up 21.3%


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025